Express Scripts, a pharmacy benefit manager and subsidiary of Cigna (CI), has reached a settlement with the FTC over accusations that it artificially inflated the prices of insulin drugs, violating ...

By Jody Godoy Feb 4 (Reuters) - Cigna Corp's Express Scripts settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and ...

Cigna signed a definitive agreement to acquire Express Scripts for $67 billion in cash and stock, including assumption of $15 billion in Express Scripts debt. Here are five things to know about the ...

“Together with Express Scripts, Cigna will further accelerate our strategy of Go Deeper, Go Local and Go Beyond by improving affordability and choice, expanding our distribution reach, and further ...

Cigna and Express Scripts are planning a merger for several reasons, one of them being “the potential entry into the healthcare industry of significant new participants,” according to a May 16 ...

Cigna subsidiary Express Scripts Inc. claimed the Federal Trade Commission's July interim report—which claims middlemen have driven up prescription drug costs and exacerbated independent pharmacies—is ...

"The FTC has taken unconstitutional actions in publishing a report that ignores the evidence provided by our company and other [pharmacy benefit managers]," said Andrea Nelson, Cigna Group's chief ...

Cigna, one of the US largest health insurers, announced the deal in March, offering $48.75 a share in cash for Express Scripts in a move aimed to cut soaring healthcare costs. The $54 billion price ...

Nation's largest Pharmacy Benefits Manager accused of gaming its drug formulary and withholding billions in rebates from PBM customers.

Dec. 19--New Jersey regulators have approved the $67 billion acquisition of Express Scripts Holding Co. by Cigna Corp., the last state to give the green light to the deal, the Bloomfield health ...

Cigna's pharmacy benefit manager Express Scripts has filed a lawsuit against the FTC over the agency's recent report on PBMs, which highlighted their contribution to soaring drug prices in the U.S.